| 1 | 复方斑蝥胶囊预防Ⅲ期结直肠癌患者术后复发转移的多中心临床研究显示文摘目的:研究复方斑蝥胶囊预防Ⅲ期结直肠癌患者术后复发转移的安全性与有效性。方法:采用多中心随机双盲安慰剂对照的临床研究方法,将141例Ⅲ期结直肠癌术后完成辅助化疗4个周期以上患者分为观察组68例,对照组73例,观察组予以复方斑蝥胶囊口服,对照组予以安慰剂口服。干预6个月后,评价两组复发转移情况,临床症状、生存质量及安全性。结果:中位随访36.5个月,观察组8例(11.8%)、对照组15例(20.6%)发生复发转移。观察组的2年无病生存率为95%,高于对照组的82%(HR=0.24,95%CI 0.07~0.85,P=0.02);与对照组相比,观察组总生活质量评分、疲乏、疼痛、气促明显改善。观察期间两组不良反应事件无明显差异,且均无严重不良反应发生。结论:复方斑蝥胶囊可延长Ⅲ期结直肠癌术后完成辅助化疗4个周期以上患者的两年无病生存率,改善症状,提高生存质量。 | 郑佳彬 王应天 关靓 李冰雪 李奇 林洪生 侯炜 刘杰 刘云鹏 张瑞明 刘牧林 田峰 | 2020 | 中国中西医结合外科杂志2020，26，1： | 13 |
| 2 | Temporal Change in Treatment Patterns of Metastatic Colorectal Cancer and Its Association with Patient Survival:A Retrospective Cohort Study Based on an Intelligent Big-Data Platform显示文摘There is a lack of high-quality,large-scale,real-world evidence from patients with metastatic colorectal cancer(mCRC),especially in China.It remains unclear whether efforts to improve the quality of care for mCRC would improve patient survival outcomes in real-world practice.On the basis of an intelligent bigdata platform,we established a large-scale retrospective cohort of mCRC patients.We investigated the temporal changes in the systemic and local treatment(resection,ablation,or radiation to liver,lung,or extrahepatic and/or extrapulmonary metastases)patterns of mCRC,and whether these changes were associated with improved overall survival(OS)over time.Between July 2012 and December 2018,3403 eligible patients were included in this research.The median OS was 42.8 months(95%confidence interval(CI),40.7–46.6)for the entire cohort,25.6 months(95%CI,24.7–26.9)for those treated with systemic therapy only,and not reached(95%CI,78.6 months–not reached)for those receiving local therapy.The utility rate of local therapy increased continuously from 37.9%in 2012–2014 to 46.9%in 2017–2018.A dramatic increase in the utility rate of either cetuximab or bevacizumab was observed since 2017(39.9%,43.2%,and 60.3%in 2012–2014,2015–2016,and 2017–2018,respectively).Compared with 2012–2014,the OS of the entire population significantly improved in 2015–2016(hazard ratio(HR)=0.87(95%CI,0.78–0.99);P=0.034),but not for patients receiving systemic therapy only(HR=0.99(95%CI,0.86–1.14);P=0.889),whereas an improved OS was found in 2015–2018 for both the entire population(HR=0.75(95%CI,0.70–0.81);P<0.001)and for patients receiving systemic therapy only(HR=0.83(95%CI,0.77–0.91);P<0.001).In summary,the quality of care for mCRC,as indicated by the utility rate of targeted and local therapies,has been continuously improving over time in this study cohort,which is associated with continuously improving survival outcomes for these patients. | Zi-Xian Wang Yi-Chen Yao Zong-Jiong Mai Wu-Hao Lin You-Sheng Huang Ying Jin Hui-Yan Luo Dong-Sheng Zhang Feng-Hua Wang Feng Wang Gong Chen Pei-Rong Ding Yun-Fei Yuan Yu-Hong Li Jin-Hua Huang Zhi-Zhong Pan Rui-Hua Xu | 2021 | Engineering2021，7，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员